https://pausecardio.fr/ 2026-10-24 weekly 1.0 https://pausecardio.fr/methode/ 2026-09-12 yearly 0.8 https://pausecardio.fr/bulletin/ 2026-10-24 weekly 0.6 https://pausecardio.fr/fiche/weight-loss-in-older-patients-with-persistent-atrial-fibrillatio/ 2026-10-24 monthly 0.5 https://pausecardio.fr/fiche/biventricular-vs-conduction-system-pacing-after-atrioventricular/ 2026-10-10 monthly 0.5 https://pausecardio.fr/fiche/impact-of-undertreated-antithrombotic-therapy-on-adverse-patient/ 2026-10-03 monthly 0.5 https://pausecardio.fr/fiche/2026-hrs-paces-scientific-statement-on-the-use-of-antiarrhythmic/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/targeted-left-ventricular-lead-placement-in-biventricular-pacing/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/pacemaker-implantation-and-atrioventricular-node-ablation-vs-pul/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/immediate-ambulatory-electrocardiographic-monitoring-in-syncope/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/half-dose-rivaroxaban-vs-antiplatelet-therapy-for-preventing-sil/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/catheter-ablation-for-symptomatic-atrial-fibrillation-pvi-sham-a/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/low-voltage-ablation-in-persistent-atrial-fibrillation-the-ideal/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/antithrombotic-therapy-after-percutaneous-coronary-intervention/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/increasing-plasma-potassium-and-risk-of-atrial-fibrillation-the/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/dual-antithrombotic-therapy-using-potent-antiplatelet-inhibitors/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/pulmonary-vein-isolation-using-pulsed-field-ablation-with-vs-wit/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/anticoagulation-for-atrial-fibrillation-with-intermediate-stroke/ 2026-08-29 monthly 0.5 https://pausecardio.fr/fiche/cardiovascular-magnetic-resonance-to-guide-defibrillator-implant/ 2026-08-29 monthly 0.5 https://pausecardio.fr/fiche/risk-of-stroke-and-tia-with-pulsed-field-compared-with-radiofreq/ 2026-08-29 monthly 0.5 https://pausecardio.fr/fiche/champion-af-and-closure-af-reconciling-contrasting-results/ 2026-08-22 monthly 0.5 https://pausecardio.fr/fiche/2026-aha-acc-clinical-performance-and-quality-measures-for-patie/ 2026-08-22 monthly 0.5 https://pausecardio.fr/fiche/impact-of-myocardial-fibrosis-and-female-sex-on-life-threatening/ 2026-08-22 monthly 0.5 https://pausecardio.fr/fiche/adjunctive-posterior-wall-isolation-for-persistent-and-long-stan/ monthly 0.5 https://pausecardio.fr/fiche/pulsed-field-ablation-as-initial-therapy-for-persistent-atrial-f/ monthly 0.5 https://pausecardio.fr/fiche/subcutaneous-defibrillator-implantation-with-or-without-defibril/ monthly 0.5 https://pausecardio.fr/fiche/catheter-ablation-versus-anti-arrhythmic-drugs-for-ventricular-t/ monthly 0.5 https://pausecardio.fr/fiche/left-atrial-appendage-closure-or-anticoagulation-for-atrial-fibr/ monthly 0.5 https://pausecardio.fr/fiche/2026-hrs-ehra-scientific-statement-on-pulsed-field-ablation-for/ monthly 0.5 https://pausecardio.fr/fiche/antithrombotic-therapy-after-successful-catheter-ablation-for-at/ monthly 0.5 https://pausecardio.fr/fiche/left-atrial-appendage-closure-or-medical-therapy-in-atrial-fibri/ monthly 0.5 https://pausecardio.fr/fiche/long-term-anticoagulation-discontinuation-after-catheter-ablatio/ monthly 0.5 https://pausecardio.fr/fiche/pulsed-field-vs-radiofrequency-ablation-for-paroxysmal-atrial-fi/ monthly 0.5 https://pausecardio.fr/fiche/left-bundle-branch-area-pacing-compared-with-biventricular-pacin/ monthly 0.5 https://pausecardio.fr/fiche/pulsed-field-or-cryoballoon-ablation-for-paroxysmal-atrial-fibri/ monthly 0.5 https://pausecardio.fr/fiche/coronary-artery-disease-management-in-patients-with-severe-aorti/ 2026-10-24 monthly 0.5 https://pausecardio.fr/fiche/icare-faster-improving-care-by-faster-risk-stratification-throug/ 2026-10-24 monthly 0.5 https://pausecardio.fr/fiche/immediate-versus-staged-complete-revascularization-in-multivesse/ 2026-10-24 monthly 0.5 https://pausecardio.fr/fiche/multidisciplinary-approach-to-antiplatelet-management-in-coronar/ 2026-10-17 monthly 0.5 https://pausecardio.fr/fiche/antiplatelet-therapy-in-the-management-of-atherosclerotic-cardio/ 2026-10-17 monthly 0.5 https://pausecardio.fr/fiche/lipid-burden-and-efficacy-of-preventive-pci-of-vulnerable-athero/ 2026-10-10 monthly 0.5 https://pausecardio.fr/fiche/percutaneous-coronary-intervention-using-sirolimus-eluting-ballo/ 2026-10-10 monthly 0.5 https://pausecardio.fr/fiche/no-touch-vs-conventional-vein-grafts-in-coronary-surgery-seven-y/ 2026-10-03 monthly 0.5 https://pausecardio.fr/fiche/stenting-technique-and-clinical-outcome-in-true-bifurcation-pci/ 2026-10-03 monthly 0.5 https://pausecardio.fr/fiche/clopidogrel-monotherapy-versus-aspirin-monotherapy-in-females-an/ 2026-09-26 monthly 0.5 https://pausecardio.fr/fiche/ultrashort-vs-standard-duration-dual-antiplatelet-therapy-in-acu/ 2026-09-19 monthly 0.5 https://pausecardio.fr/fiche/intracoronary-imaging-guided-percutaneous-coronary-intervention/ 2026-09-19 monthly 0.5 https://pausecardio.fr/fiche/protocol-based-implementation-of-early-intensive-lipid-managemen/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/timing-of-pci-in-patients-undergoing-transcatheter-aortic-valve/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/targeted-use-of-computed-tomographic-coronary-angiography-in-acu/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/prasugrel-versus-ticagrelor-in-acute-coronary-syndromes/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/milvexian-with-antiplatelet-therapy-after-acute-coronary-syndrom/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/clopidogrel-or-dual-antiplatelet-therapy-in-high-ischemic-risk-p/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/aspirin-omission-at-the-time-of-primary-percutaneous-coronary-in/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/addition-of-computed-tomography-derived-fractional-flow-reserve/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/short-term-anticoagulant-therapy-and-subclinical-leaflet-thicken/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/anticoagulation-monotherapy-vs-antiplatelet-monotherapy-after-tr/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/safety-and-efficacy-of-the-0-1-h-pathway-for-myocardial-infarcti/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/ldl-cholesterol-lowering-with-evolocumab-before-percutaneous-cor/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/fifth-universal-definition-of-myocardial-infarction-2026/ 2026-08-29 monthly 0.5 https://pausecardio.fr/fiche/transcatheter-aortic-valve-replacement-or-medical-treatment-for/ 2026-08-29 monthly 0.5 https://pausecardio.fr/fiche/multivessel-coronary-artery-bypass-grafting-via-small-thoracotom/ 2026-08-22 monthly 0.5 https://pausecardio.fr/fiche/angiography-derived-fractional-flow-reserve-to-guide-pci/ monthly 0.5 https://pausecardio.fr/fiche/coronary-revascularisation-in-patients-undergoing-tavi-individua/ monthly 0.5 https://pausecardio.fr/fiche/aspirin-versus-clopidogrel-for-chronic-maintenance-monotherapy-a/ 2026-04-11 monthly 0.5 https://pausecardio.fr/fiche/deferral-of-percutaneous-coronary-intervention-in-patients-under/ monthly 0.5 https://pausecardio.fr/fiche/intravascular-ultrasound-guided-or-angiography-guided-complex-hi/ monthly 0.5 https://pausecardio.fr/fiche/redo-surgery-versus-transcatheter-valve-in-valve-for-mitral-biop/ monthly 0.5 https://pausecardio.fr/fiche/one-year-results-of-the-selution-denovo-trial-comparing-a-strate/ monthly 0.5 https://pausecardio.fr/fiche/beta-blockers-after-myocardial-infarction-without-reduced-ejecti/ monthly 0.5 https://pausecardio.fr/fiche/2025-esc-eacts-guidelines-for-the-management-of-valvular-heart-d/ monthly 0.5 https://pausecardio.fr/fiche/clopidogrel-versus-aspirin-for-secondary-prevention-of-coronary/ monthly 0.5 https://pausecardio.fr/fiche/dapagliflozin-in-patients-undergoing-transcatheter-aortic-valve/ monthly 0.5 https://pausecardio.fr/fiche/2025-acc-aha-acep-naemsp-scai-guideline-for-the-management-of-pa/ monthly 0.5 https://pausecardio.fr/fiche/routine-cerebral-embolic-protection-during-transcatheter-aortic/ monthly 0.5 https://pausecardio.fr/fiche/implementation-of-cardiac-magnetic-resonance-imaging-in-everyday/ 2026-10-03 monthly 0.5 https://pausecardio.fr/fiche/exercise-stress-echocardiography-for-diagnosis-of-heart-failure/ 2026-09-12 monthly 0.5 https://pausecardio.fr/fiche/artificial-intelligence-enabled-acquisition-and-interpretation-f/ 2026-08-29 monthly 0.5 https://pausecardio.fr/fiche/electrocardiogram-based-deep-learning-to-prioritize-testing-for/ 2026-08-29 monthly 0.5 https://pausecardio.fr/fiche/predictive-utility-of-coronary-artery-calcium-score-added-to-the/ 2026-08-29 monthly 0.5 https://pausecardio.fr/fiche/tricuspid-regurgitation-standardized-stepwise-work-up-from-refer/ 2026-08-23 monthly 0.5 https://pausecardio.fr/fiche/comparison-of-photon-counting-and-energy-integrating-computed-co/ 2026-08-23 monthly 0.5 https://pausecardio.fr/fiche/role-of-multi-modality-cardiac-imaging-in-the-management-of-pati/ 2026-08-23 monthly 0.5 https://pausecardio.fr/fiche/coronary-ct-angiography-guided-management-of-patients-with-stabl/ 2026-08-23 monthly 0.5 https://pausecardio.fr/fiche/early-discharge-strategy-including-subcutaneous-furosemide-in-ho/ 2026-10-17 monthly 0.5 https://pausecardio.fr/fiche/digoxin-in-patients-with-symptomatic-rheumatic-heart-disease-a-r/ 2026-10-17 monthly 0.5 https://pausecardio.fr/fiche/2026-icardio-alliance-global-implementation-guidelines-on-heart/ 2026-10-03 monthly 0.5 https://pausecardio.fr/fiche/myeloperoxidase-inhibition-with-mitiperstat-in-heart-failure-wit/ 2026-09-12 monthly 0.5 https://pausecardio.fr/fiche/pulmonary-denervation-for-heart-failure-related-pulmonary-hypert/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/tricuspid-valve-intervention-in-heart-failure/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/discontinuation-of-blockers-in-stable-patients-with-previous-myo/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/effectiveness-of-nurse-coordinated-digital-supported-collaborati/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/oral-relaxin-receptor-agonist-azd5462-in-participants-with-chron/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/2026-esc-guidelines-for-the-management-of-heart-failure/ 2026-08-29 monthly 0.5 https://pausecardio.fr/fiche/2026-esc-guidelines-for-the-management-of-cardiovascular-disease/ 2026-08-29 monthly 0.5 https://pausecardio.fr/fiche/targeted-assessment-in-high-risk-patients-with-diabetes-to-ident/ 2026-08-22 monthly 0.5 https://pausecardio.fr/fiche/management-of-heart-failure-with-preserved-ejection-fraction-202/ monthly 0.5 https://pausecardio.fr/fiche/aha-acc-esc-whf-expert-consensus-document-second-universal-defin/ monthly 0.5 https://pausecardio.fr/fiche/efficacy-and-safety-of-digitalis-glycosides-in-heart-failure-a-m/ 2026-05-10 monthly 0.5 https://pausecardio.fr/fiche/tim-hf3-voice-based-prediction-of-heart-failure-hospitalization/ monthly 0.5 https://pausecardio.fr/fiche/spironolactone-in-the-treatment-of-heart-failure-spirit-hf/ monthly 0.5 https://pausecardio.fr/fiche/dapagliflozin-in-patients-hospitalized-for-heart-failure-the-dap/ monthly 0.5 https://pausecardio.fr/fiche/vericiguat-in-patients-with-chronic-heart-failure-and-reduced-ej/ monthly 0.5 https://pausecardio.fr/fiche/intravenous-ferric-carboxymaltose-in-heart-failure-with-iron-def/ monthly 0.5 https://pausecardio.fr/fiche/liberal-fluid-intake-versus-fluid-restriction-in-chronic-heart-f/ monthly 0.5 https://pausecardio.fr/fiche/digitoxin-in-patients-with-heart-failure-and-reduced-ejection-fr/ monthly 0.5 https://pausecardio.fr/fiche/complexity-of-coronary-artery-disease-in-infarct-related-cardiog/ 2026-10-10 monthly 0.5 https://pausecardio.fr/fiche/intracranial-haemorrhage-following-tenecteplase-fibrinolysis-for/ 2026-09-26 monthly 0.5 https://pausecardio.fr/fiche/infective-endocarditis-diagnosis-antibiotic-therapy-and-manageme/ 2026-09-12 monthly 0.5 https://pausecardio.fr/fiche/catheter-directed-thrombolysis-in-intermediate-high-risk-pulmona/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/response-tailored-antibiotic-treatment-duration-in-left-sided-in/ 2026-08-29 monthly 0.5 https://pausecardio.fr/fiche/conservative-oxygen-for-unresponsive-patients-after-cardiac-arre/ 2026-08-23 monthly 0.5 https://pausecardio.fr/fiche/duration-of-therapeutic-hypothermia-after-out-of-hospital-cardia/ 2026-08-26 monthly 0.5 https://pausecardio.fr/fiche/left-ventricular-unloading-in-anterior-st-segment-elevation-myoc/ 2026-08-23 monthly 0.5 https://pausecardio.fr/fiche/immediate-vs-delayed-coronary-angiography-after-cardiac-arrest-w/ 2026-08-23 monthly 0.5 https://pausecardio.fr/fiche/levosimendan-to-facilitate-weaning-from-ecmo-in-patients-with-se/ 2026-08-23 monthly 0.5 https://pausecardio.fr/fiche/2025-american-heart-association-guidelines-for-cardiopulmonary-r/ 2026-08-23 monthly 0.5 https://pausecardio.fr/fiche/2025-concise-clinical-guidance-an-acc-expert-consensus-statement/ 2026-08-23 monthly 0.5 https://pausecardio.fr/fiche/an-updated-evidence-assessment-of-the-genetic-causes-of-dilated/ 2026-09-12 monthly 0.5 https://pausecardio.fr/fiche/124i-evuzamitide-positron-emission-tomography-computed-tomograph/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/aficamten-for-symptomatic-nonobstructive-hypertrophic-cardiomyop/ 2026-08-29 monthly 0.5 https://pausecardio.fr/fiche/eplontersen-for-transthyretin-amyloid-cardiomyopathy/ 2026-08-29 monthly 0.5 https://pausecardio.fr/fiche/left-atrial-structure-and-function-clinical-outcomes-and-efficac/ 2026-08-22 monthly 0.5 https://pausecardio.fr/fiche/effect-of-sacubitril-valsartan-on-functional-and-structural-card/ 2026-08-22 monthly 0.5 https://pausecardio.fr/fiche/exploration-of-arrhythmia-burden-in-cardiac-amyloidosis-using-im/ monthly 0.5 https://pausecardio.fr/fiche/long-term-durability-of-acoramidis-efficacy-in-transthyretin-amy/ monthly 0.5 https://pausecardio.fr/fiche/genetic-counselling-implementation-in-dilated-cardiomyopathy-a-c/ monthly 0.5 https://pausecardio.fr/fiche/mavacamten-in-adolescents-with-obstructive-hypertrophic-cardiomy/ monthly 0.5 https://pausecardio.fr/fiche/clinical-care-of-family-members-of-patients-with-dilated-cardiom/ monthly 0.5 https://pausecardio.fr/fiche/2025-esc-guidelines-for-the-management-of-myocarditis-and-perica/ monthly 0.5 https://pausecardio.fr/fiche/aficamten-or-metoprolol-monotherapy-for-obstructive-hypertrophic/ monthly 0.5 https://pausecardio.fr/fiche/mavacamten-in-symptomatic-nonobstructive-hypertrophic-cardiomyop/ monthly 0.5 https://pausecardio.fr/fiche/high-intensity-exercise-programme-in-patients-with-hypertrophic/ monthly 0.5 https://pausecardio.fr/fiche/vutrisiran-in-patients-with-transthyretin-amyloidosis-with-cardi/ monthly 0.5 https://pausecardio.fr/fiche/intensive-vs-standard-blood-pressure-lowering-in-people-with-and/ 2026-10-10 monthly 0.5 https://pausecardio.fr/fiche/optimizing-blood-pressure-care-in-patients-with-resistant-hypert/ 2026-10-10 monthly 0.5 https://pausecardio.fr/fiche/cardiovascular-safety-of-orforglipron-versus-insulin-glargine-in/ 2026-10-03 monthly 0.5 https://pausecardio.fr/fiche/food-and-health-nutrition-for-prevention-and-management-of-cardi/ 2026-10-03 monthly 0.5 https://pausecardio.fr/fiche/retatrutide-a-triple-hormone-receptor-agonist-for-treatment-of-o/ 2026-10-03 monthly 0.5 https://pausecardio.fr/fiche/2026-aha-acc-acs-asnc-hrs-sca-scct-scmr-svm-guideline-for-periop/ 2026-10-03 monthly 0.5 https://pausecardio.fr/fiche/efficacy-and-safety-of-semaglutide-according-to-frailty-status-a/ 2026-09-19 monthly 0.5 https://pausecardio.fr/fiche/whole-grain-consumption-and-cardiometabolic-risk-a-meta-analysis/ 2026-09-19 monthly 0.5 https://pausecardio.fr/fiche/targeted-vitamin-d-supplementation-and-major-adverse-cardiovascu/ 2026-09-12 monthly 0.5 https://pausecardio.fr/fiche/novartis-announces-lp-a-horizon-phase-iii-topline-results-for-pe/ 2026-09-12 monthly 0.5 https://pausecardio.fr/fiche/atorvastatin-cardiovascular-events-and-disability-free-survival/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/effects-of-evolocumab-on-mortality-outcomes-in-patients-without/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/inclisiran-vs-bempedoic-acid-for-low-density-lipoprotein-cholest/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/lipoprotein-a-and-atherosclerotic-cardiovascular-disease-among-a/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/digital-outreach-to-improve-statin-refills-in-patients-with-low/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/long-term-effectiveness-of-intensive-blood-pressure-management-l/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/2026-esc-guidelines-on-cardiac-rehabilitation/ 2026-08-29 monthly 0.5 https://pausecardio.fr/fiche/vitamin-k-and-d-supplementation-in-patients-with-severe-coronary/ 2026-08-29 monthly 0.5 https://pausecardio.fr/fiche/safety-and-lipoprotein-a-lowering-effects-of-kylo-11-a-non-canon/ 2026-08-29 monthly 0.5 https://pausecardio.fr/fiche/bempedoic-acid-and-first-and-recurrent-limb-outcomes-in-statin-i/ 2026-08-22 monthly 0.5 https://pausecardio.fr/fiche/zeus-ziltivekimab-in-people-with-ascvd-ckd-and-inflammation-topl/ monthly 0.5 https://pausecardio.fr/fiche/2026-acc-aha-guideline-on-the-management-of-dyslipidemia/ monthly 0.5 https://pausecardio.fr/fiche/cardiovascular-outcomes-with-tirzepatide-versus-dulaglutide-in-t/ monthly 0.5 https://pausecardio.fr/fiche/evolocumab-in-patients-without-a-previous-myocardial-infarction/ monthly 0.5 https://pausecardio.fr/fiche/2025-aha-acc-guideline-for-the-prevention-detection-evaluation-a/ monthly 0.5 https://pausecardio.fr/fiche/efficacy-and-safety-of-baxdrostat-in-uncontrolled-and-resistant/ monthly 0.5 https://pausecardio.fr/fiche/safety-and-efficacy-of-obicetrapib-in-patients-at-high-cardiovas/ monthly 0.5 https://pausecardio.fr/fiche/oral-semaglutide-and-cardiovascular-outcomes-in-high-risk-type-2/ monthly 0.5 https://pausecardio.fr/fiche/lepodisiran-a-long-duration-small-interfering-rna-targeting-lipo/ monthly 0.5 https://pausecardio.fr/fiche/2025-focused-update-of-the-2019-esc-eas-guidelines-for-the-manag/ monthly 0.5 https://pausecardio.fr/fiche/exercise-prescriptions-for-cardiovascular-health-in-adults-2026/ 2026-10-17 monthly 0.5 https://pausecardio.fr/fiche/clinical-considerations-for-the-care-of-the-tactical-athlete-wit/ 2026-09-12 monthly 0.5 https://pausecardio.fr/fiche/acc-26-sports-and-exercise-cardiology-key-takeaways-from-the-75t/ monthly 0.5 https://pausecardio.fr/fiche/masters-athletes-with-abnormal-cardiovascular-findings-a-clinica/ monthly 0.5 https://pausecardio.fr/fiche/midlife-cardiorespiratory-fitness-and-healthy-aging-an-observati/ monthly 0.5 https://pausecardio.fr/fiche/cardiac-screening-for-conditions-associated-with-sudden-cardiac/ monthly 0.5 https://pausecardio.fr/fiche/outcomes-and-burdens-to-return-to-play-for-phenotype-negative-at/ monthly 0.5 https://pausecardio.fr/fiche/ventricular-arrhythmia-and-cardiac-fibrosis-in-endurance-experie/ monthly 0.5 https://pausecardio.fr/fiche/cardiac-arrest-during-long-distance-running-races/ monthly 0.5 https://pausecardio.fr/fiche/clinical-considerations-for-competitive-sports-participation-for/ monthly 0.5 https://pausecardio.fr/fiche/cardiopulmonary-exercise-testing-in-elite-athletes-rethinking-sp/ monthly 0.5 https://pausecardio.fr/fiche/safety-of-withdrawal-of-pharmacological-treatment-after-recovery/ 2026-09-05 monthly 0.5 https://pausecardio.fr/fiche/bruton-s-tyrosine-kinase-inhibitors-and-cardiovascular-risk-a-me/ 2026-09-03 monthly 0.5 https://pausecardio.fr/fiche/cardiovascular-risk-prediction-models-in-cancer-survivors-a-meta/ 2026-09-03 monthly 0.5 https://pausecardio.fr/fiche/years-algorithm-for-diagnosis-of-suspected-pulmonary-embolism-in/ 2026-09-03 monthly 0.5 https://pausecardio.fr/fiche/coronary-plaque-progression-after-androgen-deprivation-therapy-i/ 2026-09-03 monthly 0.5 https://pausecardio.fr/fiche/coronary-atherosclerosis-in-patients-with-cancer-and-survivors-a/ 2026-09-03 monthly 0.5 https://pausecardio.fr/fiche/diagnosis-and-management-of-cardiovascular-adverse-effects-of-ta/ 2026-09-03 monthly 0.5 https://pausecardio.fr/fiche/sacubitril-valsartan-for-the-prevention-of-anthracycline-cardiot/ 2026-09-03 monthly 0.5 https://pausecardio.fr/fiche/immune-checkpoint-inhibitor-associated-cardiovascular-toxic-effe/ 2026-09-03 monthly 0.5 https://pausecardio.fr/fiche/heart-failure-with-preserved-ejection-fraction-in-cancer-patient/ 2026-09-03 monthly 0.5 https://pausecardio.fr/fiche/sacubitril-valsartan-and-prevention-of-cardiac-dysfunction-durin/ 2026-09-03 monthly 0.5 https://pausecardio.fr/fiche/prevention-of-cancer-therapy-related-cardiac-dysfunction-and-hea/ 2026-09-03 monthly 0.5 https://pausecardio.fr/fiche/primary-cardioprotective-effect-of-sacubitril-valsartan-in-breas/ 2026-09-03 monthly 0.5 https://pausecardio.fr/fiche/extended-reduced-dose-apixaban-for-cancer-associated-venous-thro/ 2026-09-03 monthly 0.5 https://pausecardio.fr/fiche/cardiovascular-toxicity-in-patients-treated-for-childhood-cancer/ 2026-09-03 monthly 0.5 https://pausecardio.fr/fiche/rivaroxaban-for-18-months-versus-6-months-in-patients-with-cance/ 2026-09-03 monthly 0.5 https://pausecardio.fr/fiche/preventing-allogeneic-stem-cell-transplant-related-cardiovascula/ 2026-09-03 monthly 0.5